Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Mon, 08th Feb 2021 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Omega Diagnostics, up 40% at 96.98 pence, 12-month range 5.93p-126.95p. It will continue to modify its Alva-based facility to "upscale significantly" its lateral flow test production capacity as it noted a Financial Times article. The FT said the UK government has chosen three British companies to make rapid Covid-19 tests. The newspaper said Omega, SureScreen and Global Access Diagnostics have been selected by the Department of Health to produce up to 2 million lateral flow devices per day for the UK, according to two people briefed on the decision.

----------

Avacta Group, up 6.8% at 136.20 pence, 12-month range 13.00p-215.25p. Says it has entered into a commercial partnership with Mologic to accelerate to market Avacta's AffiDX SARS-CoV-2 lateral flow rapid antigen test. The pre-clinical stage biotechnology company said the partnership will provide the AffiDX antigen test a faster route to market by giving it a CE marking for professional use under rapid diagnostics firm Mologic's ISO13485 quality system.

----------

Tower Resources, up 11% at 0.56 pence, 12-month range 0.189p-0.650p. Notes its South African unit Rift Petroleum has received an updated resource at the offshore Algoa-Gamtoos license from partner New Age Energy Algoa. After reprocessing seismic data at the asset, overall portfolio volumes are 54% higher at Algoa-Gamtoos, Tower explained.

----------

AIM - LOSERS

----------

Bahamas Petroleum, down 67% at 0.68p, 12-month range 0.500p-5.722p. Bahamas said that while the Perseverance #1 well encountered hydrocarbons, commercial volumes of oil were not proven. The company said the Perseverance #1 well in the Bahamas encountered hydrocarbons, as well as successfully validating the structural model and the petroleum system. However, volumes of oil encountered "are not commercial".

----------

Tissue Regenix, down 12% at 0.65p, 12-month range 0.275p-1.280p. The company expects a revenue fall in 2020, citing the negative impact of the Covid-19 pandemic. The medical devices company expects revenue of GBP12.8 million, down 1.5% from 2019's GBP13.0 million. Its financial performance was "impacted by the ongoing coronavirus pandemic".

----------

Inland Homes, down 10% at 57.75p, 12-month range 32.00p-89.85p. The company reported a fall in full-year profit as activity was disrupted by the coronavirus pandemic. Its EPRA net asset value per share at the end of September 2020 was 103.97 pence per share, down 8.5% on a year ago due to a placing of 20.8 million new shares during the year. In a separate release, Inland Homes said Chair Terry Roydon will be standing down from the board at the conclusion of the company's annual general meeting in March. Senior Independent Director Simon Bennett will be promoted to chair,

----------

boohoo Group, down 4.5% at 348.40p, 12-month range 133.10p-433.50p. The AIM-listed online-only fashion retailer will be buying the e-commerce and digital assets and associated intellectual property rights, including customer data, related business information and inventory, of the Burton, Dorothy Perkins and Wallis brands. The GBP25.2 million deal to acquire the former Arcadia Group brands does not include any stores. boohoo said Monday's acquisition is a "significant opportunity to grow" its market share.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
15 Dec 2021 08:24

Avacta antigen lateral flow test shown to detect Omicron

(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

Read more
29 Nov 2021 11:07

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

Read more
29 Nov 2021 10:38

FDA gives Avacta the go-ahead for US chemotherapy trials

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.

Read more
2 Nov 2021 11:25

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Read more
2 Nov 2021 10:21

Avacta suspends UK Covid test sales ahead of new approval

(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.

Read more
30 Sep 2021 11:14

Avacta hails "transformative" first half despite widening loss

Avacta hails "transformative" first half despite widening loss

Read more
30 Sep 2021 09:27

Avacta losses widen as development spend increases

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.

Read more
29 Sep 2021 10:32

Avacta sees pre-clinical development milestone in LG Chem partnership

Avacta sees pre-clinical development milestone in LG Chem partnership

Read more
29 Sep 2021 09:26

Avacta gets undisclosed milestone payment from LG Chem

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Sep 2021 11:50

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Read more
18 Aug 2021 14:26

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

Read more
11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

Avacta doses first patient in chemotherapy medication trial

Read more
11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

Read more
4 Aug 2021 17:53

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.